CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $17.83.

A number of research analysts recently commented on CVRX shares. Canaccord Genuity Group upped their price objective on CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 5th. William Blair upgraded shares of CVRx from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 14th. Craig Hallum lifted their price objective on shares of CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Finally, Piper Sandler upped their target price on shares of CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th.

CVRx Trading Up 1.1 %

NASDAQ CVRX opened at $12.49 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06. CVRx has a one year low of $6.40 and a one year high of $21.04. The company has a 50-day simple moving average of $14.44 and a 200-day simple moving average of $12.64. The firm has a market capitalization of $325.19 million, a PE ratio of -4.64 and a beta of 1.34.

CVRx (NASDAQ:CVRX) last issued its earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. On average, equities analysts forecast that CVRx will post -1.91 earnings per share for the current year.

Institutional Investors Weigh In On CVRx

Several institutional investors have recently bought and sold shares of the stock. PDT Partners LLC acquired a new position in CVRx during the 3rd quarter valued at about $543,000. Centiva Capital LP bought a new position in shares of CVRx in the third quarter valued at approximately $178,000. Parkman Healthcare Partners LLC increased its stake in shares of CVRx by 52.6% during the third quarter. Parkman Healthcare Partners LLC now owns 682,897 shares of the company’s stock valued at $6,016,000 after acquiring an additional 235,277 shares during the period. State Street Corp raised its holdings in CVRx by 11.4% during the third quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after purchasing an additional 27,071 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after purchasing an additional 5,053 shares during the period. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.